Action can be found in Biotech, here’s a few that look interesting. (note: you may lose your limbs buying biotech names.)
[[CTIC]]
Joined Jan 27, 2008
7,405 Blog Posts
© Copyright 2007-2024 iBankCoin All rights reserved under penalty of bodily harm. DISCLAIMER: This is a personal web site, reflecting the opinions of its author(s). It is not a production of my employer, and it is unaffiliated with any FINRA broker/dealer. Statements on this site do not represent the views or policies of anyone other than myself. The information on this site is provided for discussion purposes only, and are not investing recommendations. Under no circumstances does this information represent a recommendation to buy or sell securities. DATA INFORMATION IS PROVIDED TO THE USERS "AS IS." NEITHER iBankCoin, NOR ITS AFFILIATES, NOR ANY THIRD PARTY DATA PROVIDER MAKE ANY EXPRESS OR IMPLIED WARRANTIES OF ANY KIND REGARDING THE DATA INFORMATION, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. Privacy Policy
Henry just grew some arms with that fucking XOMA… dude is like Shiva the Destroyer now!
_______
Props to Henry, for sure. He’s made a couple of great calls.
But that pic looks like Shiva the Ambiguously Gay Dance Instructor.
Earlier on Fast Money heard “the street’s best biotech analyst” or somesuch highly recommend ALXN. Said stuff like “hasn’t participated so far…orphan products…will be a big money maker for a long time…” Anyone know enough to agree or disagree?
ALXN looks the weakest, quite a few bear flags (not looking at fundamentals at all)
I like how GENZ looks, obviously without looking at fundamentals.
Just FYI, GENZ is a “strong sell” in terms of it’s technical and hybrid scores on the PPT. “Neutral” on its fundamental score.
ALXN isn’t covered.
Any thoughts on MEDX ? On the radar tomorrow.
btw. Citigroup put out a little note on CELG tonight..a little back and forth, but mostly positive. No upgrade or anything, Still have it at Buy, $52 target..
“..We See Attractive Entry Point for Patient Investors
At current levels, we believe the stock is pricing significantly reduced estimates… “
Name the ETF: Holdings as of 5/13/09′
Human Genome Sciences,Inc HGSI 6.60 %
Millipore Corporation MIL 5.67 %
Celera Corporation CRA 5.67 %
Genzyme Corporation(Gen’l Div)) GENZ 5.67 %
Life Technologies Corp LIFE 5.54 %
Affymetrix, Inc. AFFX 5.53 %
Celgene Corporation CELG 5.50 %
Amylin Pharmaceuticals, Inc. AMLN 5.41 %
Vertex Pharmaceuticals Inc VRTX 5.37 %
Amgen Inc. AMGN 5.30 %
OSI Pharmaceuticals, Inc. OSIP 5.23 %
Gilead Sciences, Inc. GILD 5.16 %
Cephalon, Inc. CEPH 5.15 %
Biogen Idec Inc. BIIB 5.04 %
Alexion Pharmaceuticals, Inc. ALXN 5.00 %
Illumina, Inc. ILMN 4.89 %
Nektar Therapeutics NKTR 4.53 %
Intermune Inc. ITMN 4.05 %
Myriad Genetics, Inc. MYGN 3.71 %
Sequenom Inc. SQNM 1.00 %
some more notes:
Citigroup after the bell tonight:
CNQR: initiates CNQR at BUY, $35 target. I should have posted this earlier as it happened shortly after the bell, for the after hours trade.
CSC: Reit as a Strong Call, their Strong Sell on CSC, and $30 trgt.
adds COV to Top Picks Live
on Semi’s: Add to SMTC Now; Add to ADI on Wed.
“We advise buying ADI after potentially soft results next Tuesday night (19th), and recommend buying SMTC ahead of Wed night (20th) results based on solid revenue trends. Our two favorite cyclical picks, both with 91% return, are FCS and ONNN. ADI, MXIM, SLAB and SMTC are our favored secular picks and we’re cautious on ISIL.”
note on Electronics Manufacturing Services and HP’s earnings:
..EMS investors will now look for HP’s results & outlook on Tuesday May 19th… HP exposure: SMOD 30%, JBL ~10%, SANM ~10%, FLEX ~10%, CLS ~10%.
Held CELG for 3weeks as it dithered up and down sold 300shr for a dollar profit..got tired of waiting. Keeping and eye on it, EBS also looks redy to break
Bought CTIC @ 1.18
nice one as usual RC.
$EXEL
RC, Market not supporting for longs…..waiting for correct direction..got some QID with CA….